News > COVID-19 vaccine: Sanofi, GSK report robust immune response in early-stage trials
COVID-19 vaccine: Sanofi, GSK report robust immune response in early-stage trials
Business Today | 17/05/2021 03:29 PM | Click to read full article
An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday.
Sanofi and Britain's GSK said a global Phase III trial would start in the coming weeks and involve more than 35,000 adults, with the hope of seeing the vaccine approved by the fourth quarter after having initially targeted the first half of this year before a setback.